# US 2021/0196802 A1 · Pharmaceutical composition including laminin fragments to treat or prevent the disease, disorder or symptom of tooth dentin and/or dental pulp

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196802 A1
- Document ID: US20210196802A1
- Status: Published application
- Kind: A1
- Application number: 16/825,116
- Filed: 2020-03-20
- Published: 2021-07-01
- Earliest claimed: 2019-03-20
- Applicants: Takashi Saito
- Inventors: Jia Tang; Takashi Saito
- Web page: https://patentgrep.com/patent/US20210196802A1

## CPC

- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 33/42: Phosphorus; Compounds thereof
- A61K 38/014: {from connective tissue peptides, e.g. gelatin, collagen}
- C12N 5/0654: {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
- C12N 2533/52: Fibronectin; Laminin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A pharmaceutical composition contains an integrin binding fragment for Laminin which is selected from the group consisting of Laminin 511 and Laminin 411 for treating or preventing a disease, disorder, or symptom of a tooth dentin and/or pulp or pulp tissue. A method of producing a hard tissue transplantation material includes the steps of culturing odontoblast in the presence of an integrin binding fragment for the Laminin which selected from the group consisting of Laminin 511 and Laminin 411 and obtaining a culture of odontoblast and inducing calcification or mineralization of the culture of odontoblast so as to obtain the hard tissue transplantation material.

## Claims

### Claim 1

A pharmaceutical composition for treating or preventing a disease, disorder, or symptom of a tooth dentin and/or pulp or pulp tissue, the composition comprising an integrin binding fragment for Laminin which is selected from the group consisting of Laminin 511 and Laminin 411.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition further comprises porous hydroxyapatite or type I collagen.

### Claim 3

A method of producing a hard tissue transplantation material, comprising:
culturing odontoblast in a presence of an integrin binding fragment for Laminin which is selected from the group consisting of Laminin 511 and Laminin 411 and obtaining a culture of odontoblast; and
inducing calcification or mineralization of the culture of odontoblast so as to obtain the hard tissue transplantation material.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the culturing of odontoblast is performed on a culture surface which is coated with the integrin binding fragment for Laminin selected from the group consisting of Laminin 511 and Laminin 411.

### Claim 5 (depends on 4)

The method according to claim 4, wherein a coating density of the integrin binding fragment is 1 to 8 μg/cm2.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition has a function to treat or prevent the disease, disorder or symptom of the tooth dentin and/or pulp tissue including dental caries.

### Claim 7 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the composition has a function to treat or prevent the disease, disorder or symptom of the tooth dentin and/or pulp tissue including dental caries.
